top of page


ImmunityBio begins European patient treatment with Anktiva plus BCG for bladder cancer
ImmunityBio has begun treating patients in Europe with Anktiva plus BCG for a defined form of BCG-unresponsive bladder cancer, marking an early commercial-access milestone following its existing European authorisation.

nuaxia
Nov 62 min read


European Commission approves Keytruda plus Padcev for perioperative treatment of muscle-invasive bladder cancer
The European Commission has authorised Keytruda plus Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, expanding perioperative treatment options in the EU.

nuaxia
Oct 222 min read


FDA expands Anktiva approval to high-grade papillary-only BCG-unresponsive bladder cancer
The FDA has expanded Anktiva's approval to include adults with high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer, establishing the first approved treatment specifically for this population.

nuaxia
Oct 152 min read


FDA accepts UroGen’s UGN-103 NDA for recurrent low-grade intermediate-risk bladder cancer
The submission seeks approval for a next-generation mitomycin formulation designed for intravesical treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, building on the same drug-delivery platform as FDA-approved Zusduri.

nuaxia
Aug 182 min read


FDA Approves MSD’s Keytruda Combinations with Padcev for Muscle-Invasive Bladder Cancer
The approvals expand the use of Keytruda and Keytruda Qlex alongside Padcev into the perioperative treatment setting for adults with muscle-invasive bladder cancer.

nuaxia
Jul 134 min read


FDA Approves AstraZeneca’s Imfinzi Plus BCG for High-Risk Bladder Cancer
The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care.

nuaxia
Jun 22 min read
bottom of page